newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

  • Ascendiant Capital Markets issued an updated equity research report on IGC Pharma, Inc. (NYSE: IGC).
  • The report raised its price target for IGC Pharma to $5.00 per share.
  • IGC Pharma is a clinical-stage biotechnology company using AI to develop treatments for Alzheimer's and metabolic disorders.
  • The company's lead asset, IGC-AD1, is a cannabinoid-based therapy currently in Phase 2 CALMA trials for agitation in Alzheimer's dementia.
  • IGC Pharma's pipeline includes TGR-63 targeting amyloid plaques, plus early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions.
  • The company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting.
  • The press release includes standard forward-looking statement disclaimers regarding risks such as regulatory approval, AI algorithm performance, and general economic conditions.